Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapiesDamiano Baroncini, Gıancarlo Comı, Angelo Ghezzi et al.|Multiple Sclerosis Journal|2016Cited by 68
Disease reactivation after fingolimod discontinuation in two multiple sclerosis patientsAngelo Ghezzi, Massimo Filippi, Pietro Annovazzi et al.|Journal of Neurology|2012Cited by 37
Hypomagnesaemia as a trigger of relapsing non-alcoholic Wernicke encephalopathy: a case reportDamiano Baroncini, Mauro Zaffaroni, Pietro Annovazzi et al.|Neurological Sciences|2017Cited by 10
A real world experience with fingolimod in active RRMS patients naïve to second-line agents: a 2 years, intention-to-treat, observational, single center studyDamiano Baroncini, Angelo Ghezzi, Mauro Zaffaroni et al.|Multiple Sclerosis and Demyelinating Disorders|2016Cited by 8
Long-term remission of tumefactive relapsing multiple sclerosis after alemtuzumab rescue treatment in an adolescent patientDamiano Baroncini, Mauro Zaffaroni, Pietro Annovazzi et al.|Multiple Sclerosis and Related Disorders|2020Cited by 5